Absorption: Well absorbed from PO dosage forms; absorption from extended-release dosage forms is slow but complete. IV administration results in complete bioavailability.
Distribution: Widely distributed; does not distribute into adipose tissue.
Metabolism/Excretion: 90% metabolized by the liver to several metabolites (including the active metabolites, caffeine, and 3-methylxanthine); metabolites are renally excreted; 10% excreted unchanged by the kidneys.
Half-life: Premature infants: 2030 hr; Term infants: 1125 hr; Children 14 yr: 3.4 hr; Children 617 yr: 3.7 hr; Adults: 910 hr (↑ in patients >60 yr, patients with HF or liver disease; ↓ in cigarette smokers).
(bronchodilation)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | rapid | 12 hr | 6 hr |
PO-ER | delayed | 48 hr | 824 hr |
IV | rapid | end of infusion | 68 hr |
Provided that a loading dose has been given and steady-state blood levels exist.
Contraindicated in:
Use Cautiously in:
CV: tachycardia, angina, ARRHYTHMIAS, palpitations.
GI: nausea, vomiting, anorexia.
Neuro: anxiety, headache, insomnia, irritability, SEIZURES, tremor.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
(Generic available)
IV Administration:
Elixophyllin, Theo-24, Theochron